Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963661 | 0.95 | SMN1; SMN2 (0.54) | LMNAALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL1742078 | 0.89 | TSHR (0.49) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL10696209 | 0.87 | LMNA (0.45) | LMNAALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL524255 | 0.87 | CES2 (0.50) | LMNAALDH1A1MAPK1CES1CYP3A4 | |
| SCHEMBL11461527 | 0.87 | PLA2G4B (0.50) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL9414538 | 0.86 | CES2 (0.53) | LMNAALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL10498007 | 0.86 | CES2 (0.53) | LMNAALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL9695930 | 0.86 | CES2 (0.53) | LMNAALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL8889723 | 0.86 | CES2 (0.53) | LMNAALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL9280452 | 0.86 | CES2 (0.53) | LMNAALDH1A1MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3130025-A1 | COVALENTLY CROSS-LINKED GEL ELECTROLYTES | Amtek Research International, LLC. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2611819-B1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2015176016-A1 | COVALENTLY CROSS-LINKED GEL ELECTROLYTES | AMTEK RESEARCH INTERNATIONAL LLC (US) | 2015-11-19 | — | — | WO | disclosed |
| CN-104974135-A | Targeted DNA (deoxyribonucleic acid) naphthyldiimide-structure-containing celecoxib derivatives with antitumor activity, pharmaceutical composition, and preparation method and application thereof | UNIV HEBEI | 2015-10-14 | — | — | CN | disclosed |
| CN-103880828-A | Oxide of benzisoxazole compound | LING PEIXUE | 2014-06-25 | — | — | CN | disclosed |
| US-8716531-B2 | Method for producing norbornene derivative | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-5231227-A | Optically active hydroxybenzylamine derivative and process for producing said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-07-27 | — | — | US | disclosed |
| US-5200561-A | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0311385-B1 | OPTICALLY ACTIVE HYDROXYBENZYLAMINE DERIVATIVE, OPTICALLY ACTIVE AMINE-BORON COMPOUND CONTAINING SAID DERIVATIVE, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND BY USING SAID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5130486-A | A ketoximine ether isomerized using a Lewis acid metal halide | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1992-07-14 | — | — | US | disclosed |
| US-5120853-A | Reacting optically active amine-boron complex with oxime or ketone to produce opotically active amine or alcohol compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0485069-A1 | Process for producing optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-05-13 | — | — | EP | disclosed |
| EP-0435687-A2 | Process for isomerization of oxime ethers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-07-03 | — | — | EP | disclosed |
| US-5011989-A | Asymmetric reducing agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0347027-A2 | Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them. | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| EP-0311385-A2 | Optically active hydroxybenzylamine derivative, optically active amine-boron compound containing said derivative, and process for producing optically active compound by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | PPIP5K2, INF2, IMPDH2 | LMNA 4866/4885ALDH1A1 1285/4885NPSR1 2361/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885ALDH1A1 665/4885NPSR1 3965/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885ALDH1A1 665/4885NPSR1 3965/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885ALDH1A1 665/4885NPSR1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.